PMEF
LXEO icon

Point72 Middle East FZE’s Lexeo Therapeutics LXEO Stock Holding History

Point72 Middle East FZE’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-28,578
Closed -$384K – 782
2023
Q4 		$384K Buy
+28,578
New +$355K 0.01% 897

Other funds holding LXEO

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DCP
D1 Capital Partners New York $11.2B AUM 15.78% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Point72 Middle East FZE's LXEO Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Lexeo Therapeutics (LXEO) in Q1 2024, closing a stake of 28,578 shares — an estimated $384K sold.

Point72 Middle East FZE first reported a position in LXEO in Q4 2023 and held it in 1 quarter. The position peaked at $384K in Q4 2023. 54 funds tracked by Wall St. Rank hold LXEO as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Lexeo Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 28,578 Lexeo Therapeutics shares in Q1 2024, an estimated $384K.
  • Point72 Middle East FZE first reported a position in Lexeo Therapeutics in Q4 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Lexeo Therapeutics position peaked at $384K in Q4 2023.
  • 54 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.